These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23237254)

  • 1. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
    Petersen J; Buti M
    Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
    Papatheodoridis GV
    Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
    Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Nguyen MH; Keeffe EB
    J Viral Hepat; 2009 Mar; 16(3):149-55. PubMed ID: 19236641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
    Liaw YF
    Hepatology; 2007 Feb; 45(2):266-8. PubMed ID: 17256763
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis B--treatment with nucleoside analogues.
    Leung N
    Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
    Leemans WF; Ter Borg MJ; de Man RA
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():171-82. PubMed ID: 18081660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
    Lau GK
    Liver Int; 2010 Apr; 30(4):512-20. PubMed ID: 20102511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
    Singal AK; Salameh H; Kuo YF; Fontana RJ
    Aliment Pharmacol Ther; 2013 Jul; 38(2):98-106. PubMed ID: 23713520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
    Pipili C; Cholongitas E; Papatheodoridis G
    Aliment Pharmacol Ther; 2014 Jan; 39(1):35-46. PubMed ID: 24299322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.